Lifebit, a progressive biomedical data technology and services company, has reached a huge milestone, boasting a catalog of 100 million patients in its multi-omic and health data repository.
Yesterday, (February 28), a clinical-stage biotechnology company, Redx, announced that the first participant has been dosed in a phase 1 clinical trial for RXC008.
In a seminal move coinciding with Rare Disease Day, Emmes Endpoints Solutions has taken a significant step forward in the realm of rare disease research.
In a significant move to advance the landscape of digital pathology, Proscia has announced a partnership with Pramana, an AI-enabled health tech company.
Mandziuk is vice president, project management, eClinical Development & Delivery, at ICON and she says nothing could have prepared the health industry for the global impact the Covid pandemic has had.
Last week (February 22), it was announced a recent survey conducted jointly by Climedo and Siteworks has shed light on the perspectives of more than 65 primarily European-based study physicians.
Biogen Inc. has announced a significant advancement in the treatment of amyotrophic lateral sclerosis (ALS), commonly known as motor neuron disease (MND).
In a significant move aimed at revolutionizing Central Nervous System (CNS) research, eCOA/ePRO platform provider uMotif has announced a strategic partnership with MoCA Cognition, the creators of a recognized test for early cognitive impairment detection.
Results from a phase 3 trial looking at treatment for primary biliary cholangitis (PBC) are 'genuinely exciting' and support the potential for seladelpar to raise the bar in treatment of the disease.
In the fast-evolving landscape of healthcare and pharmaceuticals, the role of technology, particularly artificial intelligence (AI), is becoming increasingly prominent.
The National Institute for Health and Care Excellence (NICE) has issued guidance recommending GSK's Omjjara (momelotinib) as a treatment option for disease-related splenomegaly.
An international initiative that recognizes, rewards, and benchmarks the reputations of pharma companies in patient engagement and centricity has opened.
Creating artificial intelligence to understand medical conditions, and not just the English language, sounds far-fetched, but this is what one CEO is achieving with an impressive foundational innovation.
Jane Kendrew changed paths after a year of her first degree knowing it was exactly the right way for her. She left university with a first class honours degree and turned down the offer of a PhD to start her dream job as a research scientist.
A clinical-stage biotechnology company creating a new class of drugs today (Feb 20) announced that a first subject has been dosed in a phase 1 clinical trial.
Patients in the US with epidermal growth factor receptor mutated (EGFRm) advanced lung cancer can now receive an important new treatment option delaying disease progression by nearly nine additional months.
The father of a boy diagnosed with acute lymphoblastic leukemia at the age of nine, inspired by his son's love of collecting, has created patches of positivity for children going through cancer treatment to collect.
dsm-firmenich, today (February 15) announces its exclusive partnership with Zerion Pharma A/S to unlock a new era in cannabinoid innovation that champions patient-centric formulations.
At most major conferences, there is usually a topic or buzzword that everyone talks about - and at this year’s SCOPE held in Orlando this week, it was no different.
Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.
Stella Vnook, a seasoned veteran in the pharmaceutical industry with extensive experience in senior leadership roles at Catalent, Merck, and Diverse Biotech, has been a prominent figure in the field, particularly in oncology, for over 25 years.
Biogen Inc. has taken a step closer to bringing its ‘groundbreaking treatment’ to patients with a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder.
Swiss multinational healthcare company, Roche, has terminated its worldwide license and collaboration agreement with Repare Therapeutics despite the company earning a $40 million milestone payment from Roche.
Japanese pharmaceutical company Shionogi has announced the first peer-reviewed publication of its phase 3 study investigating ensitrelvir to treat patients with mild to moderate COVID-19 in Japan, South Korea and Vietnam.
Outsourcing Pharma and BioPharma Reporter breaks down the key people on the move in the pharma industry. Enhanc3D Genomics, Cytomos and Cellular Origins are among the companies welcoming new faces to top jobs.
With independent pharmacies now facing significant challenges, healthcare SaaS provider Charac was pleased to announce more investment so it can accelerate a digitization drive.
Phesi’s artificial intelligence (AI) driven platform, Trial Accelerator, has reached a milestone and now contains global data from more than 100 million patients.
An artificial intelligence (AI)-powered tool from UK-based Brainomix was one of only two products to be endorsed by health assessor the National Institute of Health and Care Excellence (NICE).
Rani Therapeutics, a clinical-stage biotherapeutics company focused on the oral delivery of biologics, has announced encouraging results from its phase 1 study of RT-111, a RaniPill capsule containing an ustekinumab biosimilar, CT-P43.
Results from a new research project have been announced by technology provider Medable on the enhanced electronic informed consent (elC) in clinical trials.
No new treatments to combat the major public health issue of alcohol use disorder (AUD), have been brought to market for ten years - and with half of heavy drinkers refusing the abstinence route, new drug could be the answer.
By ArisGlobal's new GenAI council sitting for first time this month
Life sciences technology company ArisGlobal, has announced the formal charter for the new generative AI Council, which will sit for the first time this month in a bid to advance life sciences innovation.
A company building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (pathway) has announced a further extension to its series B financing round.
A husband-and-wife team keen to find a solution to an ‘NHS in crisis’ have secured $1.5 million in seed funding for their UK-based startup providing AI-powered clinical and drug prescription services for minor conditions.